Perceptive Advisors Reports 6.69% Stake in PRAX via Schedule 13G

Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd. and founder Joseph Edelman have filed a Schedule 13G disclosing a passive stake in Praxis Precision Medicines (PRAX).

Rhea-AI Filing Summary

Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd. and founder Joseph Edelman have filed a Schedule 13G disclosing a passive stake in Praxis Precision Medicines (PRAX).

• Shares owned: 1,362,503 common shares.
• Ownership percentage: 6.69 % of the 20,368,982 shares outstanding as of 30 Apr 2025.
• Control rights: The Reporting Persons hold shared voting and dispositive power over all shares; they report zero sole voting/dispositive power, indicating no unilateral control.
• Date of event: 15 Jul 2025; filing signed 22 Jul 2025.
• Filer status: Perceptive Advisors is an investment adviser (IA); Edelman is a U.S. individual; Master Fund is Cayman-based.

The certification states the securities were not acquired to influence control, confirming a passive investment posture. Perceptive’s >5 % position may draw investor attention because the healthcare-focused fund is considered a sophisticated life-sciences investor.

Insights

Portfolio Manager

TL;DR Perceptive discloses 6.7 % PRAX stake, passive intent; signals smart-money interest and could lift sentiment.

The filing reveals that Perceptive Advisors, via its Master Fund, accumulated 1.36 M PRAX shares, crossing the 5 % reporting threshold. Because Perceptive is one of the best-known biotech–focused hedge funds, its endorsement often boosts market confidence and liquidity. The lack of sole voting/dispositive power and 13G (vs. 13D) status confirm a non-activist stance, reducing near-term governance risk for current management. At roughly 6.7 %, the position is meaningful yet far from controlling, limiting potential overhang concerns. Overall, the disclosure is modestly positive and impactful because it introduces a reputable institutional holder to PRAX’s register.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PRAX shares does Perceptive Advisors own?

Perceptive Advisors’ Master Fund beneficially owns 1,362,503 Praxis Precision Medicines common shares.

What percentage of PRAX does the 1.36 M shares represent?

The stake equals 6.69 % of PRAX’s 20,368,982 outstanding shares as of 30 Apr 2025.

Is Perceptive’s filing activist or passive?

It is a Schedule 13G, indicating a passive investment with no intent to influence control.

Who signed the Schedule 13G for Perceptive Advisors?

Joseph Edelman, Managing Member of Perceptive Advisors, signed the filing on 22 Jul 2025.

Where is Praxis Precision Medicines’ headquarters?

PRAX’s principal executive office is at 99 High Street, 30th Floor, Boston, MA 02110.

What is the CUSIP number for PRAX common stock?

The CUSIP for Praxis Precision Medicines common stock is 74006W207.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/22/2025 - 09:58 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Praxis Precision Medicines, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

74006W207

(CUSIP Number)

07/15/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74006W207

1

Names of Reporting Persons

Perceptive Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,362,503.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,362,503.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,362,503.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.69 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 74006W207

1

Names of Reporting Persons

Joseph Edelman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,362,503.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,362,503.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,362,503.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.69 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 74006W207

1

Names of Reporting Persons

Perceptive Life Sciences Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,362,503.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,362,503.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,362,503.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.69 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Praxis Precision Medicines, Inc.
(b)	Address of issuer's principal executive offices: 99 High Street, 30th Floor, Boston, MA 02110
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.0001 per share (the "Common Stock") of Praxis Precision Medicines, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
(c)	Citizenship: Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 74006W207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 20,368,982 shares of Common Stock outstanding as of April 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 2, 2025. The Master Fund directly holds 1,362,503 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.
(b)	Percent of class: Perceptive Advisors: 6.69% Mr. Edelman: 6.69% Master Fund: 6.69
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
	(ii) Shared power to vote or to direct the vote: Perceptive Advisors: 1,362,503 Mr. Edelman: 1,362,503 Master Fund: 1,362,503
	(iii) Sole power to dispose or to direct the disposition of: Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
	(iv) Shared power to dispose or to direct the disposition of: Perceptive Advisors: 1,362,503 Mr. Edelman: 1,362,503 Master Fund: 1,362,503
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Perceptive Advisors LLC

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman, Managing Member
Date:	07/22/2025

Joseph Edelman

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman
Date:	07/22/2025

Perceptive Life Sciences Master Fund, Ltd.

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman, Managing Member
Date:	07/22/2025